The government has invested £47 million into the Oxford University vaccine, which has been developed in partnership with AstraZeneca.
Doubts have been raised over a much-lauded Oxford University COVID-19 vaccine which experts say could fail to prevent individuals catching the virus, after trial results emerged.
However, following the publication of detailed trial results last week, it was found that the vaccine was unable to prevent monkeys from catching the COVID-19 virus. Dr. William Haseltine, a former Harvard Medical School professor who had a pivotal role in the development of early HIV/Aids treatments, said:"All of the vaccinated monkeys treated with the Oxford vaccine became infected when challenged, as judged by recovery of virus genomic RNA from nasal secretions."
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Surprises & Doubts on 90 Day Fiancé: Before the 90 DaysVarya showed up at Geoffrey's to win him back on 90 Day Fiancé: Before the 90 Days.
Lire la suite »
Pfizer: COVID-19 Vaccine Could Arrive in OctoberPharmaceutical company Pfizer plans to expand human clinical trials for a coronavirus vaccine and include thousands of people by September, according to CNBC. What to know:
Lire la suite »
Moderna's possible coronavirus vaccine delivers preliminary but promising dataThere is positive news from two COVID-19 vaccine candidates considered frontrunners, from Moderna in the US and Oxford in the United Kingdom.
Lire la suite »
New Coronavirus Vaccine Candidate Shows Promise In Early, Limited TrialModerna, a drug manufacturer, is reporting early successes in a trial for a coronavirus vaccine that produces antibodies to fight the virus and give some immunity. Now it plans to increase its study from 45 participants to 600 — half over the age of 55.
Lire la suite »
Moderna's COVID-19 vaccine shows early promise; shares soarEarly data from Moderna Inc's COVID-19 vaccine, the first to be tested in the United States, showed that it produced protective antibodies in a small group of healthy volunteers, the company said on Monday.
Lire la suite »